Development and Characterization of Deflazacort Nanoparticles for the Treatment of Inflammatory Bowel Disease
Year: 2021
Type: article
Abstract: Inflammatory Bowel Disease (IBD) are difficult to control and the reappearance is the most challenging issue for the physicians. IBD includes Ulcerative colitis (UC) and Crohn's disease (CD) .There are various controlled and colon targeted drug delivery systems available for the treatment with a limited success rate. Nanoparticles prepared by using the colon targeted polymers such as chitosan may improve the condition of IBD due to their smaller size, unique physicochemical properties, and targeting potential. Deflazacort is a glucocorticoid used as an anti-inflammatory, immunosuppressant and commonly prescribed drug for the patient having IBD such as Ulcerative Colitis (UC) and Crohn's Disease (CD). The purpose of the present study was to prepare and evaluate the potential of eudragit coated chitosan nanoparticles of Deflazacort for the treatment of IBD by ionic gelation method. These nanoparticles were further coated with Eudragit S-100 by the solvent evaporation technique so as to prevent drug release in the stomach and small intestine. Developed Nanoparticles were subjected to various characterization tsechniques such as FTIR, particle size, scanning electron microscopy (SEM), drug entrapment efficiency and zeta potential. The efficiency of drug release from prepared formulation was studied in vitro in gastrointestinal fluids of different pH. The prepared nanoparticles demonstrated the size in the nano range. The release pattern of Deflazacort from eudragit-coated chitosan nanoparticles was observed to be pH dependent. In acidic medium, the release rate was much slower however the drug was released quickly at pH 6.8 and 7.5. Subsequently, stability study at various storage temperature was also done in which the prepared formulation showed improved stability. The zeta potential of the best chitosan preparation (F2) was found to be -30.5 mV, which confirms the stability of prepared nanosuspension. Eudragit-coated chitosan nanoparticles can be a promising carrier for colon-targeted delivery of Deflazacort found to have high encapsulation efficiency and predetermined in vitro drug release profile.
Authors: Nayna Singhai,, Rupal Dubey,, Upmanyu, Neeraj
Institution: People’s University
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4385963899